# A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers

> **NCT05874167** · PHASE1 · COMPLETED · sponsor: **Dong Wha Pharmaceutical Co. Ltd.** · enrollment: 50 (actual)

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** DW6013

## Key facts

- **NCT ID:** NCT05874167
- **Lead sponsor:** Dong Wha Pharmaceutical Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-08-08
- **Primary completion:** 2022-10-11
- **Final completion:** 2022-10-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05874167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05874167, "A Pharmacokinetic Study of DW6013 (FDC of Linagliptin and Metformin) in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05874167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*